Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.66 |
| ▸ | FLT1 | P17948 | 6/20 | 0.66 |
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7451653 | 0.92 | EGFR (0.59) | KDRFLT1EGFRMAPK14FLT4 | |
| SCHEMBL7450324 | 0.84 | KDR (0.63) | KDRFLT1EGFRMAPK14FLT4 | |
| Hydrochloric Acid SCHEMBL7451047 | 0.84 | KDR (0.75) | KDRFLT1EGFRMAPK14FLT4 | |
| SCHEMBL7460012 | 0.83 | RET (0.55) | KDRFLT1EGFRMAPK14FLT4 | |
| SCHEMBL7452247 | 0.83 | MAPK14 (0.58) | KDRFLT1EGFRMAPK14FLT4 | |
| SCHEMBL7455500 | 0.83 | KDR (0.77) | KDRFLT1EGFRMAPK14FLT4 | |
| Hydrochloric Acid SCHEMBL7455319 | 0.81 | FLT1 (0.98) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL6431182 | 0.81 | EGFR (0.54) | KDRFLT1EGFRMAPK14FLT4 | |
| SCHEMBL7454326 | 0.80 | FLT1 (1.00) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL7459846 | 0.80 | FGFR1 (0.68) | KDRFLT1EGFRMAPK14FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | KDR 3/4885FLT1 1/4885EGFR 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.